NVS News and Press, Novartis AG From 05/30/24

2024-05-30 11:54:09 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results Novartis reports Phase 3 results for IgA nephropathy treatment Novartis AG (NVS) Q1 20...

2024-05-29 14:45:14 ET Summary Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. ...

2024-05-29 11:50:26 ET More on AstraZeneca AstraZeneca: Plotting A Bold Path To $80 Billion Revenues, I'm Pausing For Breath AstraZeneca: A Triple Shot Of Income, Growth, And Value AstraZeneca: Strong In A Weak Market AstraZeneca, Daiichi Sankyo ADC misses ke...

2024-05-28 13:35:36 ET More on Travere Therapeutics Travere Therapeutics, Inc. (TVTX) Q1 2024 Earnings Call Transcript Travere Therapeutics Q1 2024 Earnings Preview Travere, CSL win conditional nod for kidney disease therapy in EU Seeking Alpha’s Quant...

2024-05-28 10:20:20 ET Summary Asahi Kasei will acquire Calliditas Therapeutics AB (publ) for $1.1 billion, representing an 83% premium to the closing price on the Stockholm exchange and a 74% premium to the Nasdaq closing price. The primary asset of interest in the acquisition is...

2024-05-28 09:44:46 ET More on Novartis Novartis: Buy This Blue-Chip Dividend Stock On Sale Now Novartis AG (NVS) Q1 2024 Earnings Call Transcript Novartis: Strong Start To The Year With Beat-And-Raise First Quarter Results ADHD diagnoses increasing, becoming...

2024-05-27 07:00:00 ET Summary Novartis is a business that has shown tremendous resiliency, operating for hundreds of years. The multinational Swiss pharmaceutical topped the analyst consensus for revenue and core EPS in Q1. Novartis' net debt load is minimal, which justifies ...

2024-05-27 01:45:30 ET Summary Gilead is sitting at one of the lowest valuations in the Big Pharma sector, with a high and sustainable 4.6% dividend yield available for new buyers. The stock has an enviable track record of rising strongly in price when turmoil hits Wall Street and...

2024-05-26 15:19:39 ET Summary Eli Lilly's shares reached new all-time highs after the company increased full-year revenue and EPS guidance. The company's growth is currently supply-constrained and the growth of tirzepatide in the near- and possibly medium-term should only be limi...

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio PR Newswire In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demons...